Skip to main navigation Skip to search Skip to main content

Consequences of anorectal cancer atlas implementation in the cooperative group setting: Radiobiologic analysis of a prospective randomized in silico target delineation study

  • Panayiotis Mavroidis
  • , Drosoula Giantsoudis
  • , Musaddiq J. Awan
  • , Jasper Nijkamp
  • , Coen R.N. Rasch
  • , Joop C. Duppen
  • , Charles R. Thomas
  • , Paul Okunieff
  • , William E. Jones
  • , Lisa A. Kachnic
  • , Niko Papanikolaou
  • , Clifton D. Fuller

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose The aim of this study is to ascertain the subsequent radiobiological impact of using a consensus guideline target volume delineation atlas. Materials and methods Using a representative case and target volume delineation instructions derived from a proposed IMRT rectal cancer clinical trial, gross tumor volume (GTV) and clinical/planning target volumes (CTV/PTV) were contoured by 13 physician observers (Phase 1). The observers were then randomly assigned to follow (atlas) or not-follow (control) a consensus guideline/atlas for anorectal cancers, and instructed to re-contour the same case (Phase 2). Results The atlas group was found to have increased tumor control probability (TCP) after the atlas intervention for both the CTV (p < 0.0001) and PTV1 (p = 0.0011) with decreasing normal tissue complication probability (NTCP) for small intestine, while the control group did not. Additionally, the atlas group had reduced variance in TCP for all target volumes and reduced variance in NTCP for the bowel. In Phase 2, the atlas group had increased TCP relative to the control for CTV (p = 0.03). Conclusions Visual atlas and consensus treatment guideline usage in the development of rectal cancer IMRT treatment plans reduced the inter-observer radiobiological variation, with clinically relevant TCP alteration for CTV and PTV volumes.

Original languageEnglish (US)
Pages (from-to)418-424
Number of pages7
JournalRadiotherapy and Oncology
Volume112
Issue number3
DOIs
StatePublished - Sep 1 2014

Funding

C.D.F. received support from the Hope Foundation /Southwest Oncology Group Dr. Charles A. Coltman, Jr. Fellowship in Clinical Trials and the National Institutes of Health Clinician Scientist Loan Repayment Program (L30 CA136381-01). CDF has served as consultant for GE Medical Systems, Inc. These funders played no role in the study design, collection, analysis, interpretation of data, manuscript writing, or decision to submit the report for publication. Portions of the data were selected for a poster presentation at ESTRO 31, May 9–12, Barcelona, Spain.

FundersFunder number
Southwest Oncology Group
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of HealthU10CA180888
National Institute of Health-National Cancer InstituteU10CA032102
Hope Foundation

    Keywords

    • Anorectal cancer
    • Atlas implementation
    • Inter-observer variation
    • Radiobiological analysis
    • Target delineation

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Radiology Nuclear Medicine and imaging

    Fingerprint

    Dive into the research topics of 'Consequences of anorectal cancer atlas implementation in the cooperative group setting: Radiobiologic analysis of a prospective randomized in silico target delineation study'. Together they form a unique fingerprint.

    Cite this